Approval · Notice of Compliance 20239 · 2018
M-CLARITHROMYCIN: Notice of Compliance 20239
Issued January 3, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20239
- Date
- January 3, 2018
- Company
- Mantra Pharma Inc.Brossard, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Canadian reference product
- BIAXIN BID (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| M-CLARITHROMYCIN | 02471388 | Cancelled Post Market |
| M-CLARITHROMYCIN | 02471396 | Marketed |
Medicinal ingredients
- CLARITHROMYCIN 250 MG per TAB
- CLARITHROMYCIN 500 MG per TAB